397,634 Shares in Organon & Co. (NYSE:OGN) Acquired by Easterly Investment Partners LLC

Easterly Investment Partners LLC bought a new stake in Organon & Co. (NYSE:OGN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 397,634 shares of the company's stock, valued at approximately $5,933,000. Easterly Investment Partners LLC owned approximately 0.15% of Organon & Co. at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in OGN. Vanguard Group Inc. lifted its holdings in Organon & Co. by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company's stock valued at $453,593,000 after purchasing an additional 218,165 shares in the last quarter. Pacer Advisors Inc. increased its position in Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock worth $166,391,000 after purchasing an additional 11,140,388 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Organon & Co. by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company's stock valued at $81,288,000 after buying an additional 82,220 shares during the period. Charles Schwab Investment Management Inc. raised its position in Organon & Co. by 0.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,333,703 shares of the company's stock valued at $49,739,000 after purchasing an additional 10,652 shares during the period. Finally, Private Management Group Inc. raised its holdings in Organon & Co. by 11.9% in the 4th quarter. Private Management Group Inc. now owns 2,119,288 shares of the company's stock valued at $31,620,000 after buying an additional 225,420 shares during the period. 77.43% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Organon & Co. Stock Up 1.1 %

NYSE OGN traded up $0.16 during trading on Monday, reaching $14.67. 738,504 shares of the company's stock were exchanged, compared to its average volume of 2,531,733. The company has a 50 day moving average price of $15.33 and a two-hundred day moving average price of $16.21. The stock has a market cap of $3.79 billion, a P/E ratio of 4.42, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The business had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. On average, equities research analysts anticipate that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were paid a dividend of $0.28 per share. The ex-dividend date was Monday, February 24th. This represents a $1.12 annualized dividend and a yield of 7.63%. Organon & Co.'s dividend payout ratio is currently 33.63%.

Wall Street Analyst Weigh In

A number of research firms have commented on OGN. Morgan Stanley decreased their price target on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Friday, February 14th. TD Cowen upgraded Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. Finally, Barclays cut their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Organon & Co. presently has an average rating of "Hold" and an average price target of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.